How Healthcare CDMOs Are Transforming Drug Development and Manufacturing
The global healthcare contract development and manufacturing organization market size was valued at USD 324.82 billion in 2025 and is projected to grow from USD 356.55 billion in 2026 to USD 751.62 billion by 2034, registering a CAGR of 9.77% during the forecast period (2026–2034).
Healthcare Contract Development and Manufacturing Organization Market Size, Share and Trends Analysis, 2026–2034
Market Overview
The global healthcare contract development and manufacturing organization market is experiencing strong expansion as pharmaceutical and biotechnology companies increasingly rely on specialized external partners for drug development, formulation, testing, and manufacturing. The growing complexity of pharmaceutical products, demand for generic and biosimilar medicines, and need for cost-efficient production capabilities are strengthening the role of contract development and manufacturing organizations (CDMOs). The global healthcare CDMO market was valued at USD 324.82 billion in 2025, with North America accounting for the largest regional share of 39.2%.
Healthcare CDMOs provide outsourced services across the pharmaceutical production lifecycle, including formulation development, analytical testing, clinical trial material production, commercial manufacturing, packaging, and quality control. These services allow pharmaceutical and biotechnology companies to access specialized expertise and manufacturing infrastructure without making equivalent investments in their own facilities.
Request Sample: http://straitsresearch.com/report/healthcare-contract-development-and-manufacturing-organization-market/request-sample
Market Size and Forecast
The global healthcare contract development and manufacturing organization market size was valued at USD 324.82 billion in 2025. The market is projected to increase from USD 356.55 billion in 2026 to USD 751.62 billion by 2034, registering a compound annual growth rate (CAGR) of 9.77% during the forecast period from 2026 to 2034.
This expansion reflects the growing use of outsourced pharmaceutical development and manufacturing services. Pharmaceutical companies are seeking external partners to manage production costs, access specialized technologies, and support the development of complex medicines. The expansion of biologics, vaccines, generic medicines, and biosimilars is also strengthening demand for scalable manufacturing capabilities.
Market Trends
Continuous Manufacturing for Biologics
Demand for scalable and consistent biologics production is encouraging healthcare CDMOs to adopt continuous manufacturing technologies. Integrated upstream and downstream processes support improved process control, consistent production, and reduced intermediate storage requirements compared with conventional batch operations. These capabilities are encouraging CDMOs to invest in flexible manufacturing platforms for complex biologics and improve operational efficiency.
Integrated Drug Development Services
Pharmaceutical companies are increasingly seeking integrated development and manufacturing support from external service providers. CDMOs are combining formulation development, analytical testing, clinical trial material production, regulatory support, and commercial manufacturing within broader service models. These arrangements can reduce technology transfer complexity and support the progression of pharmaceutical products from early development to commercial supply.
Market Drivers
Pharmaceutical Manufacturing Outsourcing
The preference for outsourced manufacturing is supporting demand for healthcare CDMO services. Pharmaceutical companies face substantial investment requirements for specialized production facilities, equipment, and regulatory compliance. Partnerships with CDMOs allow these companies to reduce infrastructure costs and focus on research, marketing, and commercialization. For example, a pharmaceutical company may outsource sterile injectable production to a CDMO with validated facilities and specialized equipment, increasing demand for external manufacturing capacity.
Generic and Biosimilar Production
The need for affordable medicines is strengthening demand for contract manufacturing services across generic drugs and biosimilars. Pharmaceutical manufacturers require cost-efficient production capabilities to serve larger treatment volumes while maintaining product quality and regulatory compliance. Generic drug companies may outsource high-volume tablet, capsule, and injectable production, while biosimilar developers may depend on specialized external manufacturing processes. These requirements support capacity expansion and create additional contract opportunities for CDMOs.
Specialized Formulation Requirements
The development of highly potent drugs, sterile injectables, and complex oral dosage forms requires specialized technical expertise and production infrastructure. Pharmaceutical companies increasingly depend on CDMOs with suitable equipment and formulation capabilities to manage these requirements. This demand supports the role of specialized service providers across pharmaceutical development and commercial manufacturing.
Market Challenges
High Infrastructure and Compliance Requirements
Specialized pharmaceutical manufacturing requires significant investment in production facilities, equipment, quality systems, and regulatory compliance. These requirements can increase operating costs and create financial barriers for CDMOs seeking to establish or expand manufacturing capacity. Maintaining validated facilities and inspection-ready operations also requires continuous attention to quality management.
Complex Manufacturing Processes
Highly potent drugs, sterile injectables, biologics, and other complex formulations require specialized production capabilities and technical expertise. CDMOs must maintain suitable equipment and skilled teams to manage different product requirements. These operational demands can make capacity expansion and production management more challenging, particularly for providers serving multiple pharmaceutical customers.
Market Opportunities
Expansion of Biologics and Advanced Therapies
The growing need for biologics, vaccines, and complex therapies creates opportunities for CDMOs with specialized manufacturing infrastructure. Investments in advanced manufacturing capabilities can help providers serve pharmaceutical companies that require scalable production and technical expertise. Capabilities in biologics, cell and gene therapies, and specialized formulations can also support the development of differentiated service portfolios.
Integrated Development and Manufacturing Partnerships
The demand for end-to-end pharmaceutical services creates opportunities for CDMOs to expand beyond individual manufacturing activities. Providers offering formulation development, analytical testing, clinical supply, regulatory support, and commercial production can support broader outsourcing relationships. Integrated services can help pharmaceutical companies reduce technology transfer complexity and coordinate development and production activities through fewer service partners.
Emerging Market Manufacturing Expansion
Pharmaceutical production investments across emerging economies create opportunities for CDMOs to serve domestic and international companies. Competitive operating costs, skilled labor availability, and expanding pharmaceutical manufacturing activities can support the development of additional contract manufacturing capacity.
Market Segmentation
The healthcare contract development and manufacturing organization market is segmented by service into contract development and contract manufacturing.
By Service
Contract manufacturing dominated the market in 2025, accounting for 62.6% of the global market share. Its leading position reflects pharmaceutical companies' preference for outsourcing large-scale production and improving operational efficiency. Demand for biologics, vaccines, and complex therapies is strengthening the need for specialized manufacturing facilities, advanced production technologies, and scalable production capacity. The segment is projected to register a CAGR of 9.31% during 2026–2034.
The contract development segment is projected to grow at a CAGR of 10.72% during the forecast period. Pharmaceutical companies require specialized formulation development, analytical testing, and regulatory support to manage increasingly complex drug molecules and development timelines. Partnerships with CDMOs provide access to technical expertise while reducing the need for in-house infrastructure investment.
Regional Analysis
North America
North America dominated the healthcare contract development and manufacturing organization market, accounting for 39.2% of global revenue in 2025. The region's market position is supported by pharmaceutical manufacturing activity and opportunities for outsourced drug development and production services.
In the U.S., the pharmaceutical manufacturing sector could establish 200 net new manufacturing sites by 2030, compared with an average of 25 new sites annually during 2020–2024. The FDA's PreCheck initiative is designed to accelerate the development of domestic drug manufacturing facilities, potentially creating additional opportunities for CDMO partnerships.
In Canada, restoring the country's historical 6% share of global clinical trials could generate more than CAD 2 billion in additional annual clinical-trial R&D spending, alongside thousands of jobs. These developments could expand demand for outsourced drug development and manufacturing services.
Asia-Pacific
Asia-Pacific is expected to be the fastest-growing regional market, registering a CAGR of 11.68% during 2026–2034. Pharmaceutical manufacturing initiatives and biopharmaceutical industry expansion across the region are supporting opportunities for outsourced development and production services.
Japan is pursuing initiatives to strengthen domestic CDMO competitiveness through workforce development and expanded biopharmaceutical manufacturing capabilities. China's pharmaceutical industry plan for 2026–2030 targets at least 20% annual growth in the innovative drug sector and pharmaceutical industry revenue of at least CNY 3.5 trillion by 2030. In India, the Department of Biotechnology targets a USD 300 billion bioeconomy by 2030, including projected contributions of USD 100 billion from biopharmaceuticals and USD 45 billion from bioservices.
Europe
Europe accounted for 28.1% of the healthcare contract development and manufacturing organization market in 2025. Government support for pharmaceutical manufacturing and specialized therapy development is contributing to the region's CDMO ecosystem.
The U.K. government has committed up to £520 million through the Life Sciences Innovative Manufacturing Fund to support pharmaceutical and biotechnology manufacturing investments. Germany's National Strategy for Gene and Cell-Based Therapies identifies domestic CDMO capabilities for gene and cell therapy starting materials as an important development indicator, supporting specialized manufacturing capacity.
Key Players in the Healthcare Contract Development and Manufacturing Organization Market
The healthcare CDMO market is moderately fragmented, with established pharmaceutical manufacturers, specialized CDMOs, biotechnology service providers, and clinical research companies participating in the competitive landscape. Companies compete through manufacturing capacity, technical expertise, regulatory compliance, quality management, production scalability, service portfolios, and global infrastructure.
Key players include:
-
Catalent Inc.
-
Flex Ltd.
-
Covance Inc.
-
Lonza Group Ltd.
-
Jabil Inc.
-
Sanmina Corporation
-
IQVIA Holdings Inc.
-
Thermo Fisher Scientific Inc.
The five leading players identified in the market—Catalent Inc., Flex Ltd., Covance Inc., Lonza Group Ltd., and Jabil Inc.—are estimated to collectively account for approximately 15–20% of global market share. This is an indicative estimate, as their exact combined share is not publicly disclosed.
Conclusion
The healthcare contract development and manufacturing organization market is projected to expand from USD 356.55 billion in 2026 to USD 751.62 billion by 2034, at a CAGR of 9.77%. Pharmaceutical manufacturing outsourcing, demand for generic and biosimilar medicines, and the need for specialized production capabilities are supporting this growth. Contract manufacturing remains the leading service segment, while contract development is projected to record the faster growth rate. North America holds the largest regional share, whereas Asia-Pacific is expected to register the fastest growth during the forecast period.
The expansion of biologics manufacturing, integrated development services, and pharmaceutical production across emerging markets is creating opportunities for healthcare CDMOs. Companies with specialized infrastructure, regulatory-compliant operations, and scalable service capabilities are positioned to address the evolving requirements of pharmaceutical and biotechnology manufacturers.


